56
Views
12
CrossRef citations to date
0
Altmetric
CASE REPORT

Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis

, , , &
Pages 632-636 | Received 02 Apr 2010, Accepted 15 Jun 2010, Published online: 02 Jan 2014

References

  • Bongartz T, Sutton A, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.
  • Ehrenreich T, Churg J. Pathology of membranous nephropathy. In: Sommers SC, editor. Pathology annual. New York: Appleton-Century-Crofts; 1968. p. 145–86.
  • Schwartz MM. Membranous glomerulonephritis. In: Jennette JC, Olson JL, Schwartz MM, Fred G, editors. Heptinstall's pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 205–52.
  • Messiaen T, M'bappé P, Boffa JJ, Khayat R, Mougenot B, Rossert J, et al. MPO-ANCA necrotizing glomerulonephritis related to rheumatoid arthritis. Am J Kidney Dis. 1998;32:E6.
  • Qarni M, Kohan DE. Pauci-immune necrotizing glomerulone-phritis complicating rheumatoid arthritis. Clin Nephrol. 2000;54:54–8.
  • Obayashi M, Uzu T, Harada T, Yamato M, Takahara K, Yamauchi A. Clinical course of bucillamine-induced nephropa-thy in patients with rheumatoid arthritis. Clin Exp Nephrol. 2003;7:275–8.
  • Yoshida A, Morozumi K, Suganuma T, Sugito K, Ikeda M, Oikawa T, et al. Clinicopathological findings of bucillamine-induced nephrotic syndrome in patients with rheumatoid arthritis. Am J Nephrol. 1991;11:284–8.
  • Tömroth T, Skrifvars B. The development and resolution of glomerular basement membrane changes associated with subep-ithelial immune deposits. Am J Pathol. 1975;79:219–36.
  • Nasr SH, Said SM, Valeri AM, Stokes MB, Masani NN, D'Agati VD, et al. Membranous glomerulonephritis with ANCA-associ-ated necrotizing and crescentic glomerulonephritis. Clin J Am Soc Nephrol. 2009;4:299–308.
  • Taniguchi Y, Yorioka N, Kumagai J, Ito T, Yamakido M, Taguchi T. Myeloperoxidase antineutrophil cytoplasmic anti-body-positive necrotizing crescentic glomerulonephritis and membranous glomerulonephropathy. Clin Nephrol. 1999; 52:253–5.
  • Kanahara K, Yorioka N, Nakamura C, Kyuden Y, Ogata S, Taguchi T, et al. Myeloperoxidase-antineutrophil cytoplasmic antibody-associated glomerulonephritis with membranous nephropathy in remission. Intern Med. 1997;36:841–6.
  • Doulton TW, Tucker B, Reardon J, Velasco N. Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomeru-lonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clin Nephrol. 2004;62:234–8.
  • Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20:1400–6.
  • Kemp E, Nielsen H, Petersen LJ, Gam AN, Dahlager J, Horn T, et al. Newer immunomodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis. Clin Nephrol. 2001;55:87–8.
  • Ashok D, Dubey S, Tomlinson I. C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with inf-liximab. Clin Rheumatol. 2008;27:261–4.
  • Simms R, Kipgen D, Dahill S, Marshall D, Rodger RS. ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy. Am J Kidney Dis. 2008;51:e11–4.
  • Ramos-Casals M, Brito-Zeron P, Mutioz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86:242–51.
  • Guignard S, Gossec L, Bandinelli F, Dougados M. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis. Clin Exp Rheumatol. 26(3) Suppl 49:S23–9.
  • Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab mono-therapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12–9.
  • Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology. 2006;119: 296–305.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.